UA107088C2 - 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину - Google Patents

5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину

Info

Publication number
UA107088C2
UA107088C2 UAA201204339A UAA201204339A UA107088C2 UA 107088 C2 UA107088 C2 UA 107088C2 UA A201204339 A UAA201204339 A UA A201204339A UA A201204339 A UAA201204339 A UA A201204339A UA 107088 C2 UA107088 C2 UA 107088C2
Authority
UA
Ukraine
Prior art keywords
salts
trifluoroethoxy
hydroxycyclohexyl
nicotinamide
dichlorophenyl
Prior art date
Application number
UAA201204339A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA107088C2 publication Critical patent/UA107088C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201204339A 2009-09-11 2010-08-09 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину UA107088C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (1)

Publication Number Publication Date
UA107088C2 true UA107088C2 (xx) 2014-11-25

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204339A UA107088C2 (xx) 2009-09-11 2010-08-09 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину

Country Status (35)

Country Link
US (1) US8227491B2 (ru)
EP (1) EP2475645B1 (ru)
JP (1) JP5604520B2 (ru)
KR (1) KR101382871B1 (ru)
CN (1) CN102639506B (ru)
AR (2) AR078352A1 (ru)
AU (1) AU2010294277B2 (ru)
BR (1) BR112012005511B8 (ru)
CA (1) CA2771493C (ru)
CL (1) CL2012000611A1 (ru)
CO (1) CO6491033A2 (ru)
CR (1) CR20120089A (ru)
CY (1) CY1114377T1 (ru)
DK (1) DK2475645T3 (ru)
EC (1) ECSP12011723A (ru)
ES (1) ES2423821T3 (ru)
HK (1) HK1172021A1 (ru)
HR (1) HRP20130869T1 (ru)
IL (1) IL217920A (ru)
IN (1) IN2012DN00763A (ru)
MA (1) MA33563B1 (ru)
MX (1) MX2012002254A (ru)
MY (1) MY161103A (ru)
NZ (1) NZ597514A (ru)
PE (1) PE20120863A1 (ru)
PL (1) PL2475645T3 (ru)
PT (1) PT2475645E (ru)
RS (1) RS52987B (ru)
RU (1) RU2541475C2 (ru)
SG (1) SG179035A1 (ru)
SI (1) SI2475645T1 (ru)
TW (1) TWI412363B (ru)
UA (1) UA107088C2 (ru)
WO (1) WO2011029827A1 (ru)
ZA (1) ZA201201599B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
MX2009003222A (es) 2006-10-04 2009-04-06 Hoffmann La Roche Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.

Also Published As

Publication number Publication date
PT2475645E (pt) 2013-08-05
CN102639506A (zh) 2012-08-15
BR112012005511A2 (pt) 2016-04-19
BR112012005511B8 (pt) 2021-05-25
CY1114377T1 (el) 2016-08-31
RU2541475C2 (ru) 2015-02-20
MY161103A (en) 2017-04-14
PL2475645T3 (pl) 2013-12-31
MX2012002254A (es) 2012-03-16
EP2475645B1 (en) 2013-07-03
TWI412363B (zh) 2013-10-21
JP2013504534A (ja) 2013-02-07
ES2423821T3 (es) 2013-09-24
CO6491033A2 (es) 2012-07-31
KR101382871B1 (ko) 2014-04-08
RS52987B (en) 2014-02-28
US20110065759A1 (en) 2011-03-17
AU2010294277B2 (en) 2015-07-09
ECSP12011723A (es) 2012-04-30
WO2011029827A1 (en) 2011-03-17
US8227491B2 (en) 2012-07-24
AU2010294277A1 (en) 2012-02-09
IL217920A0 (en) 2012-03-29
TW201114427A (en) 2011-05-01
DK2475645T3 (da) 2013-07-22
AR114032A2 (es) 2020-07-15
RU2012113924A (ru) 2013-10-20
IN2012DN00763A (ru) 2015-06-26
IL217920A (en) 2015-11-30
CR20120089A (es) 2012-03-22
NZ597514A (en) 2013-10-25
HK1172021A1 (en) 2013-04-12
ZA201201599B (en) 2012-11-28
SI2475645T1 (sl) 2013-10-30
CL2012000611A1 (es) 2012-09-07
CA2771493C (en) 2017-08-29
PE20120863A1 (es) 2012-07-23
EP2475645A1 (en) 2012-07-18
CA2771493A1 (en) 2011-03-17
CN102639506B (zh) 2014-09-03
JP5604520B2 (ja) 2014-10-08
MA33563B1 (fr) 2012-09-01
HRP20130869T1 (hr) 2013-10-25
AR078352A1 (es) 2011-11-02
KR20120048040A (ko) 2012-05-14
BR112012005511B1 (pt) 2021-03-02
SG179035A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
UA107088C2 (xx) 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
WO2013064900A8 (en) Oral immediate release formulations for substituted quinazolinones
NZ603837A (en) Novel nicotinamide derivative or salt thereof
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
CA2917096C (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
MX2013002660A (es) Heteroarilmetilamidas.
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
CL2012002621A1 (es) Polimorfo forma i, ii, iii, iv y vi de 4-trifluorometil-n-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1h)-il)-benzamida (st-246); metodo para producirlas; composicion farmaceutica; forma de dosificacion unitaria; y metodo de tratamiento de infecciones por ortopoxvirus y de eczema vacunal.
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
BR112014002915A2 (pt) inibidores de pde4 suaves
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
MX2014001860A (es) Hidrazidas del acido 3-piridin carboxilico como agentes elevadores del colesterol de lipoproteina de alta densidad (hdl).
TW201129363A (en) Novel pyridine alkaloids, preparation process thereof, and the uses of the pyridine alkaloids